BioArctic’s partner Eisai presents updated sales simulation for Leqembi® at its annual press conference
Stockholm, Sweden, March 7, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi, the world’s first fully approved disease-modifying treatment for Alzheimer's disease. According to Eisai’s simulation, Leqembi sales will reach JPY 290 billion for their financial year (FY) 2026, which ends in March 2027 and JPY 1.6 trillion in FY2032.Eisai’s presentation can be found on https://www.eisai.com/ir/library/presentations/index.html. --- This information is information that